Literature DB >> 27058204

Effect of early mobilization and rehabilitation on complications in aneurysmal subarachnoid hemorrhage.

Tanja Karic1,2, Cecilie Røe1,3, Tonje Haug Nordenmark1, Frank Becker4,3, Wilhelm Sorteberg2, Angelika Sorteberg2,3.   

Abstract

OBJECTIVE Early rehabilitation is effective in an array of acute neurological disorders but it is not established as part of treatment guidelines after aneurysmal subarachnoid hemorrhage (aSAH). This may in part be due to the fear of aggravating the development of cerebral vasospasm, which is the most feared complication of aSAH. The aim of this study was to evaluate the effect of early rehabilitation and mobilization on complications during the acute phase and within 90 days after aSAH. METHODS This was a prospective, interventional study that included patients with aSAH at the neuro-intermediate ward after aneurysm repair. The control group received standard treatment, whereas the early rehab group underwent early rehabilitation and mobilization in addition to standard treatment. Clinical and radiological characteristics of patients with aSAH, progression in mobilization, and treatment variables were registered. The frequency and severity of cerebral vasospasm, cerebral infarction acquired in conjunction with the aSAH, and acute and chronic hydrocephalus, as well as pulmonary and thromboembolic complications, were compared between the 2 groups. RESULTS Clinical and radiological characteristics of patients with aSAH were similar between the groups. The early rehab group was mobilized beginning on the first day after aneurysm repair. The significantly quicker and higher degree of mobilization in the early rehab group did not increase complications. Clinical cerebral vasospasm was not as frequent in the early rehab group and it also tended to be less severe. Each step of mobilization achieved during the first 4 days after aneurysm repair reduced the risk of severe vasospasm by 30%. Acute and chronic hydrocephalus were similar in both groups, but there was a tendency toward earlier shunt implantation among patients in the control group. Pulmonary infections, thromboembolic events, and death before discharge or within 90 days after the ictus were similar between the 2 groups. CONCLUSIONS Early rehabilitation of patients after aSAH is safe and feasible. The earlier and higher degree of mobilization does not increase neurosurgical complications. Rather, the frequency and severity of cerebral vasospasm following aSAH are alleviated and are not aggravated by early rehabilitation. Clinical trial registration no.: NCT01656317 ( www.clinicaltrials.gov ).

Entities:  

Keywords:  CPP = cerebral perfusion pressure; CTA = CT angiography; DVT = deep venous thrombosis; NIW = neuro-intermediate ward; PE = pulmonary embolism; aSAH = aneurysmal subarachnoid hemorrhage; aneurysmal subarachnoid hemorrhage; cerebral vasospasm; complications; early rehabilitation; mobilization; neurointensive care; vascular disorders

Mesh:

Year:  2016        PMID: 27058204     DOI: 10.3171/2015.12.JNS151744

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  12 in total

Review 1.  Early Mobilization in the Neuro-ICU: How Far Can We Go?

Authors:  Brian F Olkowski; Syed Omar Shah
Journal:  Neurocrit Care       Date:  2017-08       Impact factor: 3.210

2.  Effectiveness of ambulation to prevent venous thromboembolism in patients admitted to hospital: a systematic review.

Authors:  Brandyn D Lau; Patrick Murphy; Anthony J Nastasi; Stella Seal; Peggy S Kraus; Deborah B Hobson; Dauryne L Shaffer; Christine G Holzmueller; Jonathan K Aboagye; Michael B Streiff; Elliott R Haut
Journal:  CMAJ Open       Date:  2020-12-08

3.  Safety and Feasibility of Early Mobilization in Patients with Subarachnoid Hemorrhage and External Ventricular Drain.

Authors:  Bethany Young; Megan Moyer; William Pino; David Kung; Eric Zager; Monisha A Kumar
Journal:  Neurocrit Care       Date:  2019-08       Impact factor: 3.210

4.  Impact of COVID-19 Pandemic on Treatment Management and Clinical Outcome of Aneurysmal Subarachnoid Hemorrhage - A Single-Center Experience.

Authors:  Sepide Kashefiolasl; Lina Elisabeth Qasem; Nina Brawanski; Moritz Funke; Fee Keil; Elke Hattingen; Christian Foerch; Volker Seifert; Vincent Matthias Prinz; Marcus Czabanka; Juergen Konczalla
Journal:  Front Neurol       Date:  2022-03-21       Impact factor: 4.003

5.  Subarachnoid hemorrhage: management considerations for COVID-19.

Authors:  Eric J Panther; Brandon Lucke-Wold
Journal:  Explor Neuroprotective Ther       Date:  2022-03-02

Review 6.  Aneurysmal Subarachnoid Hemorrhage: the Last Decade.

Authors:  Sean N Neifert; Emily K Chapman; Michael L Martini; William H Shuman; Alexander J Schupper; Eric K Oermann; J Mocco; R Loch Macdonald
Journal:  Transl Stroke Res       Date:  2020-10-19       Impact factor: 6.829

7.  Implementation of an Automated Cerebrospinal Fluid Drainage System for Early Mobilization in Neurosurgical Patients.

Authors:  Sebastian Arts; Martine van Bilsen; Erik J van Lindert; Ronald Hma Bartels; Rene Aquarius; Hieronymus D Boogaarts
Journal:  Brain Sci       Date:  2021-05-22

8.  Long-term functional prognosis of patients with aneurysmal subarachnoid hemorrhage treated with rehabilitation combined with hyperbaric oxygen: Case-series study.

Authors:  Yong Wang; Yali Gao; Minjie Lu; Yuewei Liu
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

9.  Impact of early mobilization on discharge disposition and functional status in patients with subarachnoid hemorrhage: A retrospective cohort study.

Authors:  Masatsugu Okamura; Masaaki Konishi; Akiko Sagara; Yasuo Shimizu; Takeshi Nakamura
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817

10.  Multidisciplinary Bundle Approach in Venous Thromboembolism Prophylaxis in Patients with Non-Traumatic Subarachnoid Hemorrhage.

Authors:  Brian Phan; Lolita Fagaragan; Ali Alaraj; Keri S Kim
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.